In the latest trading session, Abbott (ABT) closed at $132.02, marking a -1.18% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.33%. Meanwhile, the Dow experienced a drop of 0.63%, and the technology-dominated Nasdaq saw a decrease of 0.22%. Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 2.09% lagged the Medical sector's loss of 0.32% and the S&P 500's gain of 4.07%.The investment community will be paying close ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 17, might help the stock move higher if these key numbers are better than expectations. On th ...

Core Viewpoint - Abbott (ABT) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine a company's fair value, leading to buying or selling actions that affect stock prices [4]. Abbott's Earnings Outlook - For the fiscal year ending December 2025, Abbott is expected to earn $5.16 per share, with a 0.2% increase in the Zacks Consensus Estimate over the past three months [8]. - The upgrade reflects an improvement in Abbott's underlying business, which is likely to drive the stock price higher as investor sentiment improves [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - Stocks rated Zacks Rank 1 have historically generated an average annual return of +25% since 1988, showcasing the effectiveness of the system [7].

Beginning July 1, 2025, a month-long giveaway contest will award 100 winners with two months' worth of Good Start® | Dr. Brown's™ Gentle Pro™ baby formula plus Dr. Brown's products (valued at $516.49) – and support families in need with a donation of formula to Baby2Baby that exceeds the total contest valueGRAND RAPIDS, Mich., July 1, 2025 /PRNewswire/ -- Today, the makers of Good Start® | Dr. Brown's™ infant formula announced a nationwide giveaway contest to support families across the country. Beginning J ...

Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference June 10, 2025 Forward-Looking Statements Certain statements in this presentation are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry's actual resul ...

Perrigo Company (PRGO) FY Conference June 10, 2025 09:00 AM ET Speaker0 Good afternoon, everyone. Thank you for sorry. Good morning, everyone. Thank you for joining us at Oppenheimer's twenty fifth Annual Consumer Growth and Ecommerce Conference. My name is Rupesh Parikh. I'm the senior food, grocery, and consumer products analyst here at Oppenheimer. I'm pleased to introduce our next presenting company, Perrigo. Joining us today are President and CEO, Patrick Lockwood Taylor and EVP and CFO, Eduardo Bezera ...

Perrigo Company (PRGO) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Company Participants Bradley Joseph - Vice President of Global Investor Relations & Corporate CommunicationsPatrick Taylor - President & CEOEduardo Bezerra - Executive VP & CFOSarah Whitaker Clemente - Director, HealthcareDaniel Biolsi - Managing Director Conference Call Participants Ethan Brown - Equity Research AnalystSusan Anderson - Managing Director & Senior AnalystKeith Devas - Analyst Operator ladies and gentlemen, and welcome to t ...

Perrigo Company (PRGO) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Speaker0 ladies and gentlemen, and welcome to the Perrigo Q1 twenty twenty five Financial Results Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Wednesday, 05/07/2025. I would now like to turn the conference over to Brad Joseph, VP, Global Investor Relations. Please go ahead. Speaker1 Good morning and good afternoon ...

Q1 2025 Earnings Presentation May 7, 2025 Bradley Joseph VP Investor Relations & Corporate Communications Forward-Looking Statements Certain statements in this presentation are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or ...

Core Insights - The company advanced its 'Three-S' Plan to stabilize, streamline, and strengthen its operations, achieving strong first-quarter results driven by infant formula and OTC brands [1][4] - The fiscal year 2025 outlook for reported net sales growth has been widened to 0% to 3% from 1% to 3%, while reaffirming other financial targets including adjusted EPS [2][38] - The company is facing macroeconomic uncertainties, including tariffs, which are expected to impact costs, but it remains confident in its financial targets due to proactive measures [4][34] Financial Performance - First-quarter 2025 net sales were $1.04 billion, a decline of 3.5% year-over-year, primarily due to divested businesses and currency translation [8][11] - Adjusted diluted EPS increased by 106.9% to $0.60, driven by higher adjusted operating income and lower interest expenses [17][10] - Reported gross margin improved to 37.6%, up 450 basis points from the prior year, while adjusted gross margin expanded to 41.0% [14][10] Segment Performance - Consumer Self-Care Americas (CSCA) net sales decreased by 3.6% to $621 million, impacted by lost distribution of lower-margin products and lack of prior year benefits from new product launches [19][21] - Consumer Self-Care International (CSCI) net sales declined by 3.4% to $423 million, although organic net sales grew by 4.5% due to strong performance in specific categories [26][27] Strategic Initiatives - Project Energize aims to deliver annualized pre-tax savings of $140 million to $170 million by the end of 2026, with $40 million to $60 million expected to be reinvested [7][6] - The company has achieved gross annual savings of approximately $159 million since the program's inception, with restructuring charges of $111 million incurred [7][6] Cash Flow and Balance Sheet - First-quarter 2025 cash from operations was a loss of $65 million, primarily due to inventory rebuilding and restructuring costs [32] - As of March 29, 2025, cash and cash equivalents were $410 million, with total debt at $3.63 billion [33][50]